KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 73 filers reported holding KALA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $68,000 | -9.3% | 22,914 | +121.7% | 0.00% | – |
| Q1 2021 | $75,000 | -34.8% | 10,335 | -32.6% | 0.00% | – |
| Q4 2020 | $115,000 | +16.2% | 15,344 | +28.2% | 0.00% | – |
| Q3 2020 | $99,000 | -28.8% | 11,973 | -10.0% | 0.00% | – |
| Q2 2020 | $139,000 | +49.5% | 13,300 | +28.8% | 0.00% | – |
| Q1 2020 | $93,000 | +173.5% | 10,328 | +15.7% | 0.00% | – |
| Q4 2019 | $34,000 | +325.0% | 8,928 | +334.2% | 0.00% | – |
| Q3 2019 | $8,000 | -69.2% | 2,056 | -48.8% | 0.00% | – |
| Q2 2019 | $26,000 | +100.0% | 4,014 | +148.5% | 0.00% | – |
| Q1 2019 | $13,000 | +1200.0% | 1,615 | +624.2% | 0.00% | – |
| Q4 2018 | $1,000 | 0.0% | 223 | +182.3% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 79 | -2.5% | 0.00% | – |
| Q2 2018 | $1,000 | – | 81 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,430,021 | $9,638,000 | 6.26% |
| RA Capital Management | 10,874,613 | $73,295,000 | 1.10% |
| Mesirow Financial Investment Management, Inc. | 41,961 | $283,000 | 0.77% |
| Samsara BioCapital, LLC | 601,162 | $4,052,000 | 0.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $689,000 | 0.38% |
| Eventide Asset Management | 3,450,000 | $23,253,000 | 0.34% |
| Orbimed Advisors | 5,465,030 | $36,834,000 | 0.34% |
| Parkman Healthcare Partners LLC | 148,433 | $1,000,000 | 0.23% |
| Vivo Capital, LLC | 786,883 | $5,304,000 | 0.19% |
| Knights of Columbus Asset Advisors LLC | 199,954 | $1,348,000 | 0.13% |